Signaturefd LLC Purchases 72 Shares of ResMed Inc. (NYSE:RMD)

Signaturefd LLC grew its position in ResMed Inc. (NYSE:RMD) by 1.7% during the third quarter, HoldingsChannel.com reports. The fund owned 4,211 shares of the medical equipment provider’s stock after acquiring an additional 72 shares during the quarter. Signaturefd LLC’s holdings in ResMed were worth $1,028,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in RMD. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in ResMed by 24.9% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 177,083 shares of the medical equipment provider’s stock worth $35,068,000 after purchasing an additional 35,273 shares during the last quarter. Mediolanum International Funds Ltd bought a new stake in shares of ResMed in the 1st quarter worth about $2,246,000. Janney Montgomery Scott LLC raised its position in shares of ResMed by 5.3% during the 1st quarter. Janney Montgomery Scott LLC now owns 81,313 shares of the medical equipment provider’s stock valued at $16,102,000 after buying an additional 4,075 shares in the last quarter. Wellington Management Group LLP bought a new position in shares of ResMed in the 4th quarter valued at about $7,535,000. Finally, State Board of Administration of Florida Retirement System grew its position in ResMed by 8.8% in the first quarter. State Board of Administration of Florida Retirement System now owns 171,632 shares of the medical equipment provider’s stock worth $37,586,000 after acquiring an additional 13,894 shares in the last quarter. Institutional investors own 54.98% of the company’s stock.

Insider Buying and Selling

In other news, CEO Michael J. Farrell sold 14,683 shares of ResMed stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $214.25, for a total value of $3,145,832.75. Following the transaction, the chief executive officer now directly owns 440,799 shares in the company, valued at approximately $94,441,185.75. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Michael J. Farrell sold 14,683 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $214.25, for a total value of $3,145,832.75. Following the sale, the chief executive officer now directly owns 440,799 shares in the company, valued at approximately $94,441,185.75. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Kaushik Ghoshal sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $252.56, for a total transaction of $1,262,800.00. Following the transaction, the insider now owns 21,788 shares of the company’s stock, valued at approximately $5,502,777.28. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 123,874 shares of company stock valued at $28,151,142 over the last 90 days. Corporate insiders own 1.21% of the company’s stock.

Analyst Upgrades and Downgrades

RMD has been the subject of several analyst reports. Wolfe Research reaffirmed an “underperform” rating and issued a $180.00 price objective on shares of ResMed in a research note on Wednesday, September 18th. Baird R W raised shares of ResMed to a “strong-buy” rating in a research note on Tuesday, September 24th. Bank of America boosted their price objective on shares of ResMed from $240.00 to $270.00 and gave the company a “buy” rating in a research report on Thursday, September 26th. Needham & Company LLC restated a “hold” rating on shares of ResMed in a report on Tuesday, October 1st. Finally, StockNews.com upgraded shares of ResMed from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th. One research analyst has rated the stock with a sell rating, five have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, ResMed currently has an average rating of “Moderate Buy” and an average price target of $218.18.

ResMed Trading Down 1.1 %

RMD opened at $237.40 on Thursday. The company has a quick ratio of 1.69, a current ratio of 2.59 and a debt-to-equity ratio of 0.14. The stock’s fifty day moving average is $239.99 and its two-hundred day moving average is $217.20. The company has a market capitalization of $34.88 billion, a P/E ratio of 36.47, a PEG ratio of 2.15 and a beta of 0.69. ResMed Inc. has a 52 week low of $132.24 and a 52 week high of $255.18.

ResMed (NYSE:RMD) last released its quarterly earnings data on Thursday, August 1st. The medical equipment provider reported $2.08 earnings per share for the quarter, beating the consensus estimate of $2.03 by $0.05. ResMed had a return on equity of 25.00% and a net margin of 21.79%. The firm had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.22 billion. During the same period in the previous year, the company posted $1.60 earnings per share. The firm’s quarterly revenue was up 6.9% on a year-over-year basis. Analysts forecast that ResMed Inc. will post 9.08 earnings per share for the current year.

ResMed Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 19th. Investors of record on Thursday, August 15th were issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 0.89%. This is a positive change from ResMed’s previous quarterly dividend of $0.48. The ex-dividend date was Thursday, August 15th. ResMed’s dividend payout ratio (DPR) is presently 32.57%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.